#CGEN

StockTitan

@stocktitan.net

1 week ago

Compugen Reports Fourth Quarter and Full Year 2025 Results Compugen (Nasdaq: CGEN) reported Q4 and full‑year 2025 results and a corporate update on March 2, 2026. Key items: $145.6M cash at year‑end, $65M upfront from AstraZeneca royalty monetization, expected cash runway into 2029, and CEO transition to Eran Ophir.2025 revenue totaled $72.8M (Q4 $67.3M); net income was $35.3M for the year and Q4 net profit was $56.8M. Clinical progress includes COM701 MAIA‑ovarian and Gilead‑partnered GS‑0321 trials with MAIA interim analysis expected Q1 2027.

#CGEN Compugen Reports Fourth Quarter and Full Year 2025 Results

www.stocktitan.net/news/CGEN/compugen-repor...

Thiard News@F4F

@newsen.bsky.social

1 month ago

Compugen Welcomes Michele Holcomb, Ph.D. as New Board Member to Accelerate Growth Compugen Ltd. has appointed Michele Holcomb, Ph.D., as a new independent director. Her extensive experience in biotech and healthcare will bolster the company’s strategic direction.

Compugen Welcomes Michele Holcomb, Ph.D. as New Board Member to Accelerate Growth #Compugen #Holon #CGEN #Michele_Holcomb

Lym | Vgen comms open

@lymqv0.bsky.social

1 month ago

Emote comm on vgen
#vgencomm #cgen

StockTitan

@stocktitan.net

2 months ago

#CGEN Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

www.stocktitan.net/news/CGEN/compugen-monet...

StockTitan

@stocktitan.net

4 months ago

#CGEN Compugen Reports Third Quarter 2025 Results

www.stocktitan.net/news/CGEN/compugen-repor...

Thiard News@F4F

@newsen.bsky.social

4 months ago

Compugen Announces Upcoming Q3 2025 Financial Results and Corporate Update Compugen Ltd., a leader in cancer immunotherapy, will release its third quarter 2025 financial results on November 10, before U.S. markets open, with updates on its pipeline.

Compugen Announces Upcoming Q3 2025 Financial Results and Corporate Update #Israel #Immunotherapy #Compugen #Holon #CGEN

StockTitan

@stocktitan.net

4 months ago

DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’ s DATROWAY in combination with rilvegostomig in previously untreated, cisplatin ineligible patients TROPION-Urothelial03 phase 2/ 3 trial initiated to further evaluate the role of DATROWAY plus platinum-based...

#AZN #CGEN DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial

www.stocktitan.net/news/AZN/datroway-plus-r...

StockTitan

@stocktitan.net

7 months ago

#CGEN Compugen Reports Second Quarter 2025 Results

www.stocktitan.net/news/CGEN/compugen-repor...

StockTitan

@stocktitan.net

7 months ago

Breakthrough Immunotherapy Trial Launches for Platinum-Sensitive Ovarian Cancer Treatment First-in-class antibody therapy shows promise for ovarian cancer maintenance treatment, backed by 18-month response data. See trial timeline and efficacy targets.

#CGEN Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

www.stocktitan.net/news/CGEN/compugen-annou...

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Small-cap stocks with strong volume gains, Thu Jul 17th - #VVPR #PDYN #NNDM #MCRI #ADV #BZAI #CGEN #DPRO #EPIX #HYPR #XXII #SAIH #OPEN #LAZR #IRIX #WDH #SPCE #NMG #LAC #IH #BRCC #WINT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

9 months ago

Major Breakthrough: ENHERTU Enters Phase 3 Trial for First-Line Endometrial Cancer Treatment - New Hope for HER2 Patients First patient dosed in groundbreaking Phase 3 trial combining ENHERTU with immunotherapy for advanced endometrial cancer. See how this could transform treatment.

#AZN #CGEN DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer

www.stocktitan.net/news/AZN/destiny-endomet...

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Most searched small-cap stocks, Tue Jun 3rd - #CIFR #RSLS #VLRS #TNGX #SEDG #PSIX #NVTS #MCTR #LTBR #LEU #KULR #KIDZ #GRYP #DNN #CGEN #CATX #BTCS #ASPI #APLD #AI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

9 months ago

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer AstraZeneca and Daiichi Sankyo reported promising results for DATROWAY (datopotamab deruxtecan) in treating non-small cell lung cancer (NSCLC) across three clinical trials presented at ASCO 2025. In TROPION-Lung02, the combination of DATROWAY with pembrolizumab showed a 54.8% objective response rate in the doublet arm and 55.6% in the triplet arm including chemotherapy. TROPION-Lung04 demonstrated a 57.5% response rate when combining DATROWAY with rilvegostomig. The NeoCOAST-2 trial showed encouraging results in early-stage NSCLC with a 35.2% pathologic complete response rate when combining DATROWAY with durvalumab and chemotherapy. Safety profiles were consistent with previous studies, with manageable adverse events including some cases of interstitial lung disease.

#AZN #CGEN DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

www.stocktitan.net/news/AZN/datroway-contin...

StockTitan

@stocktitan.net

9 months ago

Compugen Reports Major Cancer Trial Progress: AstraZeneca Launches 10 Phase 3 Studies, Strong Cash Position AstraZeneca expands rilvegostomig to 10 Phase 3 trials. New ovarian cancer study launched. $103.7M cash extends runway to 2027. See full pipeline updates.

#CGEN Compugen Reports First Quarter 2025 Results

www.stocktitan.net/news/CGEN/compugen-repor...

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Small-cap stocks with bullish moving average convergence divergence crossovers, Thu May 15th - #NCT #ABSI #BVS #CGEN #HRZN #IMKTA #JBSS #LILA #MNRO #OESX #ZIP #SQNS #RGR #MBC #KLG #GLP #CMRE #AZUL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

Compugen's Cancer Immunotherapy Pipeline Gains Momentum With $103M War Chest Through 2027 Compugen reports improved 2024 financials with $103.3M cash runway into 2027, while advancing COM701 trials and expanding partnerships with AstraZeneca and Gilead.

#CGEN Compugen Reports Fourth Quarter and Full Year 2024 Results

www.stocktitan.net/news/CGEN/compugen-repor...

Thiard News@F4F

@newsen.bsky.social

1 year ago

Compugen to Feature in Fireside Chat at Upcoming Global Healthcare Conference in Miami Beach Compugen Ltd. will present a fireside chat during the upcoming Leerink Partners Global Healthcare Conference in Miami Beach, offering insights on their cancer immunotherapy advancements.

Compugen to Feature in Fireside Chat at Upcoming Global Healthcare Conference in Miami Beach #United_States #Immunotherapy #Compugen #Miami_Beach #CGEN

StockTitan

@stocktitan.net

1 year ago

How Compugen's AI Platform Partnership Could Revolutionize Cancer Immunotherapy Discovery Compugen integrates Ultima's single-cell sequencing into its Unigen platform to gain deeper insights into tumor biology and accelerate immunotherapy discovery.

#CGEN Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

www.stocktitan.net/news/CGEN/compugen-enhan...

StockTitan

@stocktitan.net

1 year ago

Earnings Alert: Compugen Sets Date for Critical Year-End Financial Report & Strategic Update Compugen announces Q4 and FY2024 results release on March 4, featuring management presentation and investor conference call to discuss performance

#CGEN Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

www.stocktitan.net/news/CGEN/compugen-to-re...

StockTitan

@stocktitan.net

1 year ago

Compugen Launches First-in-Class Cancer Trial with Novel IL-18 Antibody COM503 Compugen doses first patient in Phase 1 trial of COM503, a groundbreaking IL-18 binding protein antibody licensed to Gilead, targeting advanced solid tumors with innovative approach.

#CGEN Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

www.stocktitan.net/news/CGEN/compugen-annou...

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #CGEN ) Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #CGEN ) Compugen to Present at Single Cell Genomics 2024 Conference

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #CGEN ) Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

#StockMarket #News